Agree_老虎社区_美港股上老虎

donovanng92
2021-06-22

Agree

With Merger Complete, Here’s Tilray’s Roadmap to Profitability

TLRY stock is looking better following its Aphria merger. Tilray(NASDAQ:TLRY) stock is arguably mos

With Merger Complete, Here’s Tilray’s Roadmap to Profitability

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":129900635,"tweetId":"129900635","gmtCreate":1624349074727,"gmtModify":1631888361618,"author":{"id":4087350196307800,"idStr":"4087350196307800","authorId":4087350196307800,"authorIdStr":"4087350196307800","name":"donovanng92","avatar":"https://static.tigerbbs.com/d3554a7357e094d9c2ce0e9bd0e1e942","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>Agree</body></html>","htmlText":"<html><head></head><body>Agree</body></html>","text":"Agree","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/129900635","repostId":1195017896,"repostType":4,"repost":{"id":"1195017896","pubTimestamp":1624346717,"share":"https://www.laohu8.com/m/news/1195017896?lang=&edition=full","pubTime":"2021-06-22 15:25","market":"us","language":"en","title":"With Merger Complete, Here’s Tilray’s Roadmap to Profitability","url":"https://stock-news.laohu8.com/highlight/detail?id=1195017896","media":"InvestorPlace","summary":"TLRY stock is looking better following its Aphria merger.\n\nTilray(NASDAQ:TLRY) stock is arguably mos","content":"<blockquote>\n TLRY stock is looking better following its Aphria merger.\n</blockquote>\nTilray(NASDAQ:TLRY) stock is arguably most famous for soaring to $300 per share soon after its initial public offering. Since then, it’s been all downhill for the Canadian marijuana company.\nTilray’s years of underperformance could be coming to an end, however. Recently, the company merged with another large marijuana producer, Aphria. The combined company appears to be on a path toward profitability.\nThere are no guarantees, but it seems the worst is finally over for TLRY stock.\nWhy Tilray Has Struggled\nIt’s no secret that the Canadian cannabis market has been vastly oversupplied since the government legalized recreational use. However, the tide appeared to be turning in early 2020 as supply and demand started to find a balance.\nThe coronavirus upset that fragile equilibrium, however. As Tilray’s chairman and CEO Irwin Simonrecently explained, Canada’s lockdowns slammed Tilray and Aphria’s operations. American readers may not realize, but Canada finally just started allowing retail cannabis shops to have in-person shopping again, and even now, it’s only at 10% of normal capacity.\nHaving retail essentially shut down (curbside pickup and online only) for a year was disastrous for such a new market as recreational cannabis.\nTilray is planning on upping its marketing and outreach to consumers once its stores are back to normal operating hours. As you can imagine, however, it made little sense to push marketing aggressively at a time when people couldn’t shop in person.\nCFO Carl Merton explained Tilray’s view of the marketing work it needs to do once stores are open again.\n<blockquote>\n There’s a lot of consumers out there today that need education [… about] the potency in regards to the different flower, in regards to the different pre rolls out there, certain decisions on vapes, on price, et cetera. So you got to go back and react pretty quickly. And as the stores open, we have some pretty aggressive strategic plans in place of how we’re going to do it, both on new products, social media, getting products out there, getting a pipeline filled again.\n</blockquote>\nIt’s fair to blame Tilray and Aphria to some extent for missing expectations. But there has been a real headwind that was outside of their control, so management deserves some benefit of the doubt for now. Let’s see if Tilray’s team can execute on the game plan that Merton described.\nMarket Share is the Main Objective\nAccording to Simon, the combined Tilray and Aphria enterprise currently has 17% of the Canadian market. His goal is to get Tilray to 30% market share going forward.\nTilray has a three-pronged plan to make this happen. First, it will invest in its brands to help consumers find and get comfortable with Tilray’s offerings. Second, it is going into adjacent products such as drinks and edibles. Right now, Tilray has very little exposure to this area, so any success here would meaningfully improve its market share. Finally, Tilray is making a push into the medical marijuana market as well.\nA big problem for the Canadian marijuana companies has been a lack of operating scale. Costs have simply been too high for each independent company. As Tilray sells more and more marijuana, however, it gets to spread those expenses across a much larger operating base.\nIt’s become clear that marijuana isn’t an easy road to incredible fortunes. However, the business should still be able to work for companies with superior operations. Tilray is making a concerted effort to be that industry leader.\nTilray’s Recent Price Surge and Subsequent Crash\nTilray’s shares went from $10 in January to $60 at one point and are now back at $17. If it wasn’t fundamental developments that caused the extreme volatility, then what happened?\nSimply put, traders tried to turn Tilray into a meme stock. Its shares surged at the same time that other r/WallStreetBets favorites also shot up to the moon. It made sense in theory. Cannabis stocks tend to have high retail interest;Sundial Growers(NASDAQ:SNDL) has been a favorite onRobinhoodand social media all year. Plus, Tilray seemed to have a massive short position in it. That, in turn, could catalyze a big squeeze, right?\nWhat this line of reasoning missed, however, was that this short interest was largely artificial. People weren’t short-selling Tilray so much to bet against the company. Rather, it was part of a merger arbitrage situation where folks were buying Aphria and selling Tilray to capture the spread before those companies joined forces. As this was mechanical trading, rather than normal bearish short selling, it didn’t create a lasting squeeze as we’ve seen at other meme stocks.\nNow that the Aphria merger closed and it’s one combined company, the merger arbitrage folks have gotten out of the Tilray short position. In other words, it didn’t and still doesn’t make sense to own TLRY stock based on a short squeeze thesis. The real upside comes if the company’s merger with Aphria works and produces a dominant industry leader.\nTLRY Stock Verdict\nCan 1 plus 1 equal 3? That’s the question for Tilray going forward. Tilray never accomplished all that much as an independent company. Neither did Aphria. But perhaps the two of them together can be a greater force than either one was on its own.\nThat’s the hope anyway if you own TLRY stock. At least one of these Canadian-focused marijuana companies is bound to be successful sooner or later. Combining forces to gain operating scale and efficiency seems logical.\nIt’s hard to get too excited about Tilray just yet given its past problems. But management seems to be on the right path with the Aphria deal and now it’s time to see if the combined firm can finally reach its potential.","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>With Merger Complete, Here’s Tilray’s Roadmap to Profitability</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWith Merger Complete, Here’s Tilray’s Roadmap to Profitability\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-22 15:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/heres-roadmap-to-profitability-tlry-stock/>InvestorPlace</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nTLRY stock is looking better following its Aphria merger.\n\nTilray(NASDAQ:TLRY) stock is arguably most famous for soaring to $300 per share soon after its initial public offering. Since then, it’s been...\n\n<a href=\"https://investorplace.com/2021/06/heres-roadmap-to-profitability-tlry-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TLRY":"Tilray Inc."},"source_url":"https://investorplace.com/2021/06/heres-roadmap-to-profitability-tlry-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1195017896","content_text":"TLRY stock is looking better following its Aphria merger.\n\nTilray(NASDAQ:TLRY) stock is arguably most famous for soaring to $300 per share soon after its initial public offering. Since then, it’s been all downhill for the Canadian marijuana company.\nTilray’s years of underperformance could be coming to an end, however. Recently, the company merged with another large marijuana producer, Aphria. The combined company appears to be on a path toward profitability.\nThere are no guarantees, but it seems the worst is finally over for TLRY stock.\nWhy Tilray Has Struggled\nIt’s no secret that the Canadian cannabis market has been vastly oversupplied since the government legalized recreational use. However, the tide appeared to be turning in early 2020 as supply and demand started to find a balance.\nThe coronavirus upset that fragile equilibrium, however. As Tilray’s chairman and CEO Irwin Simonrecently explained, Canada’s lockdowns slammed Tilray and Aphria’s operations. American readers may not realize, but Canada finally just started allowing retail cannabis shops to have in-person shopping again, and even now, it’s only at 10% of normal capacity.\nHaving retail essentially shut down (curbside pickup and online only) for a year was disastrous for such a new market as recreational cannabis.\nTilray is planning on upping its marketing and outreach to consumers once its stores are back to normal operating hours. As you can imagine, however, it made little sense to push marketing aggressively at a time when people couldn’t shop in person.\nCFO Carl Merton explained Tilray’s view of the marketing work it needs to do once stores are open again.\n\n There’s a lot of consumers out there today that need education [… about] the potency in regards to the different flower, in regards to the different pre rolls out there, certain decisions on vapes, on price, et cetera. So you got to go back and react pretty quickly. And as the stores open, we have some pretty aggressive strategic plans in place of how we’re going to do it, both on new products, social media, getting products out there, getting a pipeline filled again.\n\nIt’s fair to blame Tilray and Aphria to some extent for missing expectations. But there has been a real headwind that was outside of their control, so management deserves some benefit of the doubt for now. Let’s see if Tilray’s team can execute on the game plan that Merton described.\nMarket Share is the Main Objective\nAccording to Simon, the combined Tilray and Aphria enterprise currently has 17% of the Canadian market. His goal is to get Tilray to 30% market share going forward.\nTilray has a three-pronged plan to make this happen. First, it will invest in its brands to help consumers find and get comfortable with Tilray’s offerings. Second, it is going into adjacent products such as drinks and edibles. Right now, Tilray has very little exposure to this area, so any success here would meaningfully improve its market share. Finally, Tilray is making a push into the medical marijuana market as well.\nA big problem for the Canadian marijuana companies has been a lack of operating scale. Costs have simply been too high for each independent company. As Tilray sells more and more marijuana, however, it gets to spread those expenses across a much larger operating base.\nIt’s become clear that marijuana isn’t an easy road to incredible fortunes. However, the business should still be able to work for companies with superior operations. Tilray is making a concerted effort to be that industry leader.\nTilray’s Recent Price Surge and Subsequent Crash\nTilray’s shares went from $10 in January to $60 at one point and are now back at $17. If it wasn’t fundamental developments that caused the extreme volatility, then what happened?\nSimply put, traders tried to turn Tilray into a meme stock. Its shares surged at the same time that other r/WallStreetBets favorites also shot up to the moon. It made sense in theory. Cannabis stocks tend to have high retail interest;Sundial Growers(NASDAQ:SNDL) has been a favorite onRobinhoodand social media all year. Plus, Tilray seemed to have a massive short position in it. That, in turn, could catalyze a big squeeze, right?\nWhat this line of reasoning missed, however, was that this short interest was largely artificial. People weren’t short-selling Tilray so much to bet against the company. Rather, it was part of a merger arbitrage situation where folks were buying Aphria and selling Tilray to capture the spread before those companies joined forces. As this was mechanical trading, rather than normal bearish short selling, it didn’t create a lasting squeeze as we’ve seen at other meme stocks.\nNow that the Aphria merger closed and it’s one combined company, the merger arbitrage folks have gotten out of the Tilray short position. In other words, it didn’t and still doesn’t make sense to own TLRY stock based on a short squeeze thesis. The real upside comes if the company’s merger with Aphria works and produces a dominant industry leader.\nTLRY Stock Verdict\nCan 1 plus 1 equal 3? That’s the question for Tilray going forward. Tilray never accomplished all that much as an independent company. Neither did Aphria. But perhaps the two of them together can be a greater force than either one was on its own.\nThat’s the hope anyway if you own TLRY stock. At least one of these Canadian-focused marijuana companies is bound to be successful sooner or later. Combining forces to gain operating scale and efficiency seems logical.\nIt’s hard to get too excited about Tilray just yet given its past problems. But management seems to be on the right path with the Aphria deal and now it’s time to see if the combined firm can finally reach its potential.","news_type":1},"isVote":1,"tweetType":1,"viewCount":348,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["ADC"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":5,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}